Artivion Balance Sheet Health
Financial Health criteria checks 3/6
Artivion has a total shareholder equity of $304.7M and total debt of $314.0M, which brings its debt-to-equity ratio to 103%. Its total assets and total liabilities are $803.1M and $498.4M respectively. Artivion's EBIT is $28.9M making its interest coverage ratio 1. It has cash and short-term investments of $56.2M.
Key information
103.0%
Debt to equity ratio
US$313.97m
Debt
| Interest coverage ratio | 1x |
| Cash | US$56.17m |
| Equity | US$304.74m |
| Total liabilities | US$498.41m |
| Total assets | US$803.14m |
Recent financial health updates
Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28
Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Recent updates
Why Investors Shouldn't Be Surprised By Artivion, Inc.'s (NYSE:AORT) P/S
Jan 09Artivion: Current Valuation Seems Stretched.
Dec 26Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)
Dec 19When Should You Buy Artivion, Inc. (NYSE:AORT)?
Nov 07Returns At Artivion (NYSE:AORT) Are On The Way Up
Sep 28Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)
Sep 06Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28Data-Driven Growth Fuels More Upside For Overlooked Artivion
Jun 21Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Financial Position Analysis
Short Term Liabilities: AORT's short term assets ($288.0M) exceed its short term liabilities ($152.8M).
Long Term Liabilities: AORT's short term assets ($288.0M) do not cover its long term liabilities ($345.6M).
Debt to Equity History and Analysis
Debt Level: AORT's net debt to equity ratio (84.6%) is considered high.
Reducing Debt: AORT's debt to equity ratio has increased from 77.8% to 103% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AORT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AORT is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 11.8% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 22:37 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Jason Mills | Canaccord Genuity |
| Raymond Myers | Emerging Growth Equities, Ltd. |